An observational study in Parenteral Nutrition and Blood Stream Infection, sponsored by Fresenius Kabi. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.
Sponsored by Fresenius Kabi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary study objective is to assess the rates of blood stream infection (BSI) from the use of Three-Chamber Bags (e.g., SmofKabiven®, Kabiven®, others) compared to Hospital Compounded Bags (HCBs) in patients requiring parenteral nutrition in Spanish hospitals.
This is a retrospective observational database study of patients receiving parenteral nutrition (PN) for at least 3 consecutive days with hospital admission date between January 1, 2013, and December 31, 2015 (study period).
The study will use an as treated approach, where patients will be followed from the index date (hospital admission day of the hospitalization during which PN is administered) up to patient discharge or death (observation period).
The study will be conducted using an initial EMR (Electronic Medical Record) data retrieval process, followed by manual data retrieval (chart review) that will complement data obtained from EMR. Data collection for manual data retrieval will be conducted through an eCRF.
The documentation of patient data will comprise two sequential steps. The initial step will include data of 30% of patients and then an interim analysis (IA) will be conducted. If IA shows positive results, data for the remaining 70% of patients (step II) will be gathered.
The study will be conducted in 10-14 sites in Spain.
Data analysis: Baseline demographics, co-morbidities, and hospitalization characteristics will be reported descriptively by means of mean with standard deviations and medians with ranges for continuous variables and by counts and percentages for categorical variables. Incidence rates for BSI will be reported by treatment group.
Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Population will include adult hospitalized patients receiving PN, treated on any ward and by any medical discipline within the hospital (e.g., intensive care unit, normal wards; surgery, non-surgery) during the study period. For every patient, one hospitalization episode will be documented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Groups with different parenteral nutrition bags (3CBs or HCBs)
Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB)
Confirmation of BSI required fulfillment of all of the following criteria: * International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for sepsis (038.x), septicemia (995.91), severe sepsis (995.92), septic shock (785.52), bacteremia (790.7), unspecified infection due to central venous catheter (999.31), or BSI due to central venous catheter (999.32) * Positive blood culture collected during PN administration * Concomitant antimicrobial therapy
Time frame: Entire study period, from January 1, 2013 and December 31, 2015
Sepsis During PN
Percentage of patients presenting at least one episode of Sepsis during treatment with PN for each group (3CB vs HCB)
Time frame: From date of admission to date of discharge
Treatment With Antimicrobials During PN
Percentage of patients receiving antimicrobial agents during treatment with PN for each group (3CB vs HCB)
Time frame: Any day during PN treatment
Use of Vasopressor Treatment
Percentages of patients requiring vasopressor support during PN treatment
Time frame: Patients requiring vasopressor support at any time during treatment with PN
Use of Mechanical Ventilation
Percentage of patients requiring mechanical ventilation during PN treatment for each group (3CB vs HCB)
Time frame: Patients requiring mechanical ventilation at any time during PN treatment
Renal Replacement Therapy
Percentage of patients requiring Renal Replacement Therapy during PN treatment for each group (3CB vs HCB)
Time frame: Patients requiring renal replacement therapy for at least one day during PN treatment
Newly-occurred Abnormal Laboratory Findings During PN
Percentage of patients presenting newly-occurred abnormal laboratory results during PN for each group (3CB vs HCB)
Time frame: During PN treatment inclusive day 1
Organ Failure
Percentage of patients presenting at least one organ failure during treatment with PN for each group (3CB vs HCB)
Time frame: Any time during PN treatment
Hospital Length of Stay (LOS)
Hospital length of stay in days for patients for each group (3CB vs HCB)
Time frame: Duration in days from admission to death or discharge for each treatment arm
Length of Stay in the ICU
Total number of days in the ICU for each group (3CB vs HCB)
Time frame: All patients admitted in the ICU at any time during PN treatment
Retrospective cohort study. Data collection from medical records
| Milestone | Three-chambered Bag (3CB) | Hospital-Compounded Bag (HCB) |
|---|---|---|
| Started | 2753 | 970 |
| Completed | 2753 | 970 |
| Not completed | 0 | 0 |
Confirmation of BSI required fulfillment of all of the following criteria: * International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for sepsis (038.x), septicemia (995.91), severe sepsis (995.92), septic shock (785.52), bacteremia (790.7), unspecified infection due to central venous catheter (999.31), or BSI due to central venous catheter (999.32) * Positive blood culture collected during PN administration * Concomitant antimicrobial therapy
| Participants | Three-Chambered Bag | Hospital-compounded Bag |
|---|---|---|
| Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB) | 127 | 106 |
Percentage of patients presenting at least one episode of Sepsis during treatment with PN for each group (3CB vs HCB)
| Participants | Three-Chambered Bag (3CB) | Hospital-Compounded Bag (HCB) |
|---|---|---|
| Sepsis During PN | 431 | 228 |
Percentage of patients receiving antimicrobial agents during treatment with PN for each group (3CB vs HCB)
| Participants | Three-chambered Bag (3CB) | Hospital-Compounded Bag (HCB) |
|---|---|---|
| Treatment With Antimicrobials During PN | 831 | 370 |
Percentages of patients requiring vasopressor support during PN treatment
| Participants | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Use of Vasopressor Treatment | 410 | 291 |
Percentage of patients requiring mechanical ventilation during PN treatment for each group (3CB vs HCB)
| Participants | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Use of Mechanical Ventilation | 410 | 299 |
Percentage of patients requiring Renal Replacement Therapy during PN treatment for each group (3CB vs HCB)
| Participants | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Renal Replacement Therapy | 78 | 89 |
Percentage of patients presenting newly-occurred abnormal laboratory results during PN for each group (3CB vs HCB)
| Participants | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Metabolic impairment | 1193 | 584 |
| Any hepatic dysfunction | 1414 | 651 |
| Any abnormal electrolytes | 1444 | 699 |
Percentage of patients presenting at least one organ failure during treatment with PN for each group (3CB vs HCB)
| Participants | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Any organ failure | 905 | 562 |
| Single organ failure | 593 | 255 |
| Multiple organ failure | 312 | 307 |
Hospital length of stay in days for patients for each group (3CB vs HCB)
| Days | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Hospital Length of Stay (LOS) | 26,601 | 30,384 |
Total number of days in the ICU for each group (3CB vs HCB)
| Days | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) |
|---|---|---|
| Length of Stay in the ICU | 3,017 | 3,772 |
Collected over Retrospective, observational, non-interventional study. All-cause mortality, Serious and Other (Not Including Serious) Adverse Events were not monitored/assessed. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Three-Chambered Bag (3CB) | — | — | — |
| Hospital-compounded Bag (HCB) | — | — | — |
A total of 5389 patient records were screened for eligibility; of these, 3723 met the selection criteria, including 2753 patients who received 3CB and 970 patients who received MCB
| Age, Continuous(years) | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) | Total |
|---|---|---|---|
| Mean | 66.8 ± 15.2 | 66.5 ± 14.8 | 66.8 ± 15.2 |
| Sex: Female, Male(Participants) | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) | Total |
|---|---|---|---|
| Female | 1144 | 354 | 1498 |
| Male | 1609 | 616 | 2225 |
| Race and Ethnicity Not Collected(Participants) | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Three-Chambered Bag (3CB) | Hospital-compounded Bag (HCB) | Total |
|---|---|---|---|
| Spain | 2753 | 970 | 3723 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in May 2019, 17 months.
Results were first posted in Jan 2021, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.